PMID- 30768766
OWN - NLM
STAT- MEDLINE
DCOM- 20200427
LR  - 20200427
IS  - 1467-789X (Electronic)
IS  - 1467-7881 (Linking)
VI  - 20
IP  - 6
DP  - 2019 Jun
TI  - Semaglutide as a promising antiobesity drug.
PG  - 805-815
LID - 10.1111/obr.12839 [doi]
AB  - Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a long 
      elimination half-life, allowing subcutaneous (sc) administration once per week. 
      Both the European Medicines Agency (EMA) and the Food and Drug Administration 
      (FDA) recently approved once-weekly sc semaglutide for the treatment of type 2 
      diabetes mellitus (T2DM). The weight loss efficacy of once-weekly sc semaglutide 
      appears to be superior compared with the other once-weekly GLP-1 RAs in patients 
      with T2DM. Semaglutide was recently evaluated as an antiobesity drug in a phase 
      II dose-finding trial, which demonstrated superior weight loss efficacy of once 
      daily sc semaglutide compared with both placebo and once daily 3.0 mg liraglutide 
      in patients with obesity but without T2DM. The magnitude of semaglutide-induced 
      weight loss in this study exceeded the criteria of both the EMA and FDA for 
      antiobesity drugs, and there were no safety concerns, indicating the eligibility 
      of once daily sc semaglutide as a future antiobesity drug.
CI  - (c) 2019 World Obesity Federation.
FAU - Christou, Georgios A
AU  - Christou GA
AD  - School of Medicine, University of Ioannina, Ioannina, Greece.
FAU - Katsiki, Niki
AU  - Katsiki N
AD  - Second Propedeutic Department of Internal Medicine, Medical School, Aristotle 
      University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.
FAU - Blundell, John
AU  - Blundell J
AD  - Institute of Psychological Sciences, Faculty of Medicine and Health, University 
      of Leeds, Leeds, UK.
FAU - Fruhbeck, Gema
AU  - Fruhbeck G
AD  - Metabolic Research Laboratory, Clinica Universidad de Navarra, CIBEROBN, 
      Pamplona, Spain.
FAU - Kiortsis, Dimitrios N
AU  - Kiortsis DN
AUID- ORCID: 0000-0002-2082-3747
AD  - School of Medicine, University of Ioannina, Ioannina, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190215
PL  - England
TA  - Obes Rev
JT  - Obesity reviews : an official journal of the International Association for the 
      Study of Obesity
JID - 100897395
RN  - 0 (Anti-Obesity Agents)
RN  - 53AXN4NNHX (semaglutide)
RN  - 62340-29-8 (Glucagon-Like Peptides)
SB  - IM
MH  - Anti-Obesity Agents/*therapeutic use
MH  - Glucagon-Like Peptides/*therapeutic use
MH  - Humans
MH  - Obesity/*drug therapy
OTO - NOTNLM
OT  - glucagon-like peptide-1 receptor agonist
OT  - obesity
OT  - semaglutide
OT  - weight loss
EDAT- 2019/02/16 06:00
MHDA- 2020/04/28 06:00
CRDT- 2019/02/16 06:00
PHST- 2018/11/28 00:00 [received]
PHST- 2019/01/15 00:00 [revised]
PHST- 2019/01/20 00:00 [accepted]
PHST- 2019/02/16 06:00 [pubmed]
PHST- 2020/04/28 06:00 [medline]
PHST- 2019/02/16 06:00 [entrez]
AID - 10.1111/obr.12839 [doi]
PST - ppublish
SO  - Obes Rev. 2019 Jun;20(6):805-815. doi: 10.1111/obr.12839. Epub 2019 Feb 15.